Display options
Cite
Ueshiba H, Tsuboi K, Miyachi Y. Effects of amlodipine on serum levels of adrenal androgens and insulin in hypertensive men with obesity. Horm Metab Res. 2001;33(3):167-9doi: 10.1055/s-2001-14932.
Ueshiba, H., Tsuboi, K., & Miyachi, Y. (2001). Effects of amlodipine on serum levels of adrenal androgens and insulin in hypertensive men with obesity. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 33(3), 167-9. https://doi.org/10.1055/s-2001-14932
Ueshiba, H, et al. "Effects of amlodipine on serum levels of adrenal androgens and insulin in hypertensive men with obesity." Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme vol. 33,3 (2001): 167-9. doi: https://doi.org/10.1055/s-2001-14932
Ueshiba H, Tsuboi K, Miyachi Y. Effects of amlodipine on serum levels of adrenal androgens and insulin in hypertensive men with obesity. Horm Metab Res. 2001 Mar;33(3):167-9. doi: 10.1055/s-2001-14932. PMID: 11355751.
Copy Download .nbib Format: NLM
Share it on

Horm Metab Res. 2001 Mar;33(3):167-9. doi: 10.1055/s-2001-14932.

Effects of amlodipine on serum levels of adrenal androgens and insulin in hypertensive men with obesity.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme

H Ueshiba, K Tsuboi, Y Miyachi

Affiliations

  1. First Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan. [email protected]

PMID: 11355751 DOI: 10.1055/s-2001-14932

Abstract

We investigated the effects of the calcium channel blocker amlodipine besilate on serum levels of adrenal androgens and insulin in 20 men with essential hypertension and obesity (age: 51.9+/-4.7 years, body mass index: 27.7+/-1.5 kg/m2). All were treated with amlodipine besilate (Norvasc) for 3 months. Blood pressure, fasting plasma glucose (FPG), HbA1c and serum levels of insulin, dehydroepiandrosterone (DHEA), DHEA sulfate (DHEA-S), and lipids were measured before and after a 3-month period. In 10 patients, 75 g oral glucose tolerance test (75 g-OGTT) was also performed. Amlodipine besilate treatment 1) lowered the fasting serum insulin level and total serum insulin level during 75 g-OGTT and 2) increased serum DHEA and DHEA-S levels. No changes in fasting plasma glucose, HbA1c and serum lipids were observed during treatment. We conclude that amlodipine besilate improves insulin resistance and consequently increases serum DHEA and DHEA-S levels.

Substances

MeSH terms

Publication Types